Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo.
PLoS One 2015 Sep 25; 10(9):e0135513
Targeting dendritic cell-specific endocytic receptors using monoclonal antibodies fused to desired antigens is an approach widely used in vaccine development to enhance the poor immunogenicity of protein-based vaccines and to induce immune responses. Here, we engineered an anti-human DCIR recombinant antibody, which cross-reacts with the homologous cynomolgous macaque receptor and was fused via the heavy chain C-terminus to HIV Gagp24 protein (αDCIR.Gagp24). In vitro, αDCIR.Gagp24 expanded multifunctional antigen-specific memory CD4+ T cells recognizing multiple Gagp24 peptides from HIV-infected patient peripheral blood mononuclear cells. In non human primates, priming with αDCIR.Gagp24 without adjuvant elicited a strong anti-Gagp24 antibody response after the second immunization, while in the non-targeted HIV Gagp24 protein control groups the titers were weak. The presence of the double-stranded RNA poly(I:C) adjuvant significantly enhanced the anti-Gagp24 antibody response in all the groups and reduced the discrimination between the different vaccine groups. The avidity of the anti-Gagp24 antibody responses was similar with either αDCIR.Gagp24 or Gagp24 immunization, but increased from medium to high avidity in both groups when poly(I:C) was co-administered. This data provides a comparative analysis of DC-targeted and non-targeted proteins for their capacity to induce antigen-specific antibody responses in vivo. This study supports the further development of DCIR-based DC-targeting vaccines for protective durable antibody induction, especially in the absence of adjuvant. PLoS One 2015 Sep 25; 10(9):e0135513
Flamar, Anne-Laure; Contreras, Vanessa; Zurawski, Sandra; Montes, Monica; Dereuddre-Bosquet, Nathatlie; Martinon, Frédéric; Banchereau, Jacques; Le Grand, Roger; Zurawski, Gerard; and Levy, Yves, "Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo." (2015). Faculty Research 2015. 162.